Koneksa Health

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries. Learn more at:

[Koneksa Health @Koneksa]

Koneksa announces positive topline results from KH007, a 12-month study evaluating digital measures of PD progression. Read the #PressRelease to learn how the study met its primary endpoint: https://t.co/HAk7iHbeVg

[Koneksa Health @Koneksa]

AI can spin up an EDC system in minutes, but speed isn't the same as trust. Hear why on the @SCDM_DataDriven podcast with @crscube, featuring Koneksa's Mike Mendoza: https://t.co/GeewExIbQv

[Koneksa Health @Koneksa]

In clinical development, the right partner matters before, during, and especially when plans change. See how Koneksa helped support @IntensityInc, when they needed it most.

We’re proud to work as an extension of the Intensity team, bringing biometrics expertise, EDC optimization, Lodestar™ software, and scientific strategy together to help strengthen execution in a complex rescue study. Need a partner who can step in, stabilize, and strengthen your study? Contact Koneksa today to discuss how we can help.

[Koneksa Health @Koneksa]

#AlzheimersAndBrainAwarenessMonth is a reminder of the millions waiting on better treatments. Across the field, there's growing agreement on what will get us there faster. Here's where the conversation is heading: https://t.co/PWkaZluRVR

#DigitalBiomarkers #ClinicalTrials #NeuroscienceResearch #AlzheimersDisease #ParkinsonsDisease

[Koneksa Health @Koneksa]

The launch was just the beginning. Download the fact sheet to see exactly how our ai-assisted 10-step pipeline stacks up against the traditional process. The Lodestar™ difference speaks for itself: https://t.co/4a6sRIEKYP

[Koneksa Health @Koneksa]

The path from database lock to regulatory filing has been fragmented for too long. That changes today. Introducing Lodestar™, Intelligent Submission Software for #ClinicalTrials. Read the full #PressRelease: https://t.co/u0USwyEWeY

Lodestar™ connects EDC ingest through eCTD assembly in one AI-assisted, auditable workflow, with human approval before each step advances. Built for FDA and EMA submissions, Lodestar™ is now available in early access for select sponsor and CRO partners.

[Koneksa Health @Koneksa]

In asthma, more data isn’t the answer. Meaning is. This #WorldAsthmaDay, explore how advanced modeling and AI-enabled approaches are translating respiratory data into decision-ready evidence: https://t.co/uGWPJNEAQd

Koneksa integrates digital, physiological, and clinical data and applies longitudinal modeling to reduce variability and clarify signal, with AI-enabled methods expanding how these signals in respiratory and beyond are identified, contextualized, and carried through to submission-ready evidence. Explore how this approach can strengthen your respiratory study and support faster, more confident decisions.

[Koneksa Health @Koneksa]

#CNSClinicalTrials are often limited by how we measure change. Our latest white paper explores how #DigitalEndpoints can improve sensitivity and interpretability. Download the #WhitePaper today: https://t.co/wzUkRv9k7s

[Koneksa Health @Koneksa]

Announcing an exciting milestone for Koneksa! Database lock has been achieved for the KH007, a Koneksa-sponsored study in #ParkinsonsDisease progression. Read the full #PressRelease: https://t.co/LBTIc4aMEo #PDResearch

[Koneksa Health @Koneksa]

Not all inefficiency in clinical research is operational. Some of it starts with how we measure. This #EarthDay, it’s worth considering the downstream impact of getting that wrong.

When measurement isn’t fit for purpose, studies run longer and collect more than needed. Better measurement design doesn’t just improve decisions. It reduces unnecessary effort across the system, helping move the industry toward more efficient, sustainable progress.

[Koneksa Health @Koneksa]

Behind every dataset is a lived experience. In advance of #WorldParkinsonsDay, explore new peer-reviewed research shaping how that experience is defined and measured: https://t.co/05OZu9n7lP

We are proud to contribute to a growing body of research guided by both patient and clinician perspectives. This work helps ensure what is measured more closely reflects the aspects of Parkinson’s that matter most in daily life and reinforces the importance of advancing science that reflects real patient experience. #ParkinsonsAwarenessMonth

[Koneksa Health @Koneksa]

Newly published #PeerReviewedResearch in #PD examines how clinicians and patients define meaningful disease impacts. Read the publication to see where perspectives align, and where they diverge: https://t.co/9ukwuJJsHD

Motor symptoms were consistently prioritized by both groups, while non-motor impacts like depression and fatigue were rated more highly by patients. The distinction offers a closer look at how meaningful disease impact is interpreted, and why #MeasurementMatters. #ParkinsonsDiseaseResearch

[Koneksa Health @Koneksa]

Biometrics isn’t just about analyzing clinical data. It shapes how #clinicaltrials are designed, #endpoints are operationalized, and evidence is generated. See how flexible biometric services can help your next study succeed through expertise, not luck: https://t.co/8jrNpWnZne

[Koneksa Health @Koneksa]

#MedidataNEXT NY may be over, but the conversations it sparked are just getting started. It was a busy week for Koneksa connecting with partners across the @Medidata ecosystem. If we didn’t connect at the conference, let’s continue the conversation: https://t.co/DLI0lnFhAM

[Koneksa Health @Koneksa]

Headed to #MedidataNEXT with a team focused on getting more from your trial data. From database builds to data management and modeling, we support execution across the @Medidata ecosystem and beyond. Learn more: https://t.co/vPWArTSUWA

[Koneksa Health @Koneksa]

Rare diseases demand precision - more than you can imagine. For the 300 million people worldwide living with a rare disease, progress depends on turning complexity into clarity. Learn more and join the global movement: https://t.co/29RWJLmqRy #RareDiseaseDay

[Koneksa Health @Koneksa]

Newly formalized. Long-established execution. We're proud to announce our partnership with @Medidata, bringing measurement-first thinking to the platform many sponsors know and trust. Connect with us at #MedidataNext to learn more: https://t.co/eUYCPIugrB

[Koneksa Health @Koneksa]

Representative enrollment is essential. But if measurement or trial execution introduce bias, evidence remains incomplete. During #BlackHistoryMonth, we examine what inclusive, decision-ready evidence requires. Read more: https://t.co/tTR6Wv3uMH #ClinicalTrials #HealthEquity

[Koneksa Health @Koneksa]

An npj Digital Medicine study adds to growing evidence that passive, continuous #DigitalMeasures can track cognition and affective state over time, but only when designed with the right measurement strategy. Learn more: https://t.co/vWYycjHoyC #MeasurementMatters